Last reviewed · How we verify
continuation of aspirin therapy
The continuation of aspirin therapy, marketed by Hadassah Medical Organization, holds a well-established position in the therapeutic landscape. A key strength lies in the protection offered by the key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | continuation of aspirin therapy |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
- Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma (NA)
- Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm (NA)
- Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery (NA)
- Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuation of aspirin therapy CI brief — competitive landscape report
- continuation of aspirin therapy updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI